06.24.2024
Alivexis, an FTI-backed drug discovery company with operations in Japan and the United States, has entered into an exclusive license agreement with Swiss-based Melodia Therapeutics, valued at up to $275 million. This deal grants Melodia Therapeutics the global rights to develop, manufacture, and commercialize Alivexis’s developed Cathepsin C inhibitor, MDI-0151, a potential best-in-class drug candidate identified through its MOD-A drug discovery program. Tomo Anzai, Managing Partner of FTI, serves as an External Board of Director of Alivexis.
Alivexis is advancing its proprietary small molecule drug portfolio and various R&D partnerships, focusing on creating groundbreaking medicines for cancer, chronic and acute immune-inflammatory diseases, and rare diseases.
Melodia Therapeutics plans to commence IND-enabling activities for MDI-0151, aiming to provide innovative therapies for several unmet medical needs, including ANCA-associated vasculitis.
This milestone agreement marks a significant achievement for FTI’s investment strategy, reinforcing its commitment to advancing innovative therapeutics to address critical healthcare challenges worldwide.
About Alivexis
Founded in August 2016, Alivexis, Inc. is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, the company is propelling forward its distinct portfolio of small molecule drugs along with a variety of research and development collaborations. At present, Alivexis is dedicated to swiftly bringing innovative medications to individuals and their families grappling with cancer, both chronic and acute immune-inflammatory conditions, and rare diseases. For more information, visit https://alivexis.com.
About Fast Track Initiative
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community, including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan. Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
Media Contact
For press inquiries or investor inquiries, please email: message.us@fasttrackinitiative.com
